Patents by Inventor Maxim DURAND

Maxim DURAND has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD24CD38transitional B cells and CD9 as new biomarker of long-term human lung allograft survival
    Patent number: 11761960
    Abstract: The present invention relates to an in vitro method for determining the risk of occurrence of chronic lung graft dysfunction in a human subject comprising: a) measuring the level of CD9+ B cells in a blood sample of the subject, b) comparing the level of CD9+ B cells measured at step a) with one or more reference values of the level of CD9+ B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: September 19, 2023
    Assignees: UNIVERSITE DE NANTES, INSTITUT NATIONALE DE LE SANTE ET DE LA RECHERCHE MEDICALE, CHU NANTES
    Inventors: Carole Brosseau, Maxim Durand, Antoine Magnan, Sophie Brouard
  • CD24HICD38HI TRANSITIONAL B CELLS AND CD9 AS NEW BIOMARKER OF LONG-TERM HUMAN LUNG ALLOGRAFT SURVIVIAL
    Publication number: 20200057064
    Abstract: The present invention relates to an in vitro method for determining the risk of occurrence of chronic lung graft dysfunction in a human subject comprising: a) measuring the level of CD9+ B cells in a blood sample of the subject, b) comparing the level of CD9+ B cells measured at step a) with one or more reference values of the level of CD9+ B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).
    Type: Application
    Filed: April 27, 2018
    Publication date: February 20, 2020
    Inventors: Carole BROSSEAU, Maxim DURAND, Antoine MAGNAN, Sophie BROUARD